Eligibility for photodynamic therapy (PDT) with verteporfin based on either the TAP or the VIP studies guidelines in eyes with subfoveal CNV (89 out of 269 eyes)
| Eyes meeting the TAP Study guidelines | Eyes meeting the VIP Study guidelines | Eyes not meeting the current guidelines for PDT with verteporfin | |
|---|---|---|---|
| *1 eye had a VA <20/200 and CNV occupying less than 50% of the total area of the lesion. | |||
| 22 (8% of all eyes) | 31 (12%) | 36 (13%) | |
| • 21 eyes: | occult CNV with fibrovascular retinal PEDs | ||
| • 4 eyes: | predominantly occult (or minimally classic) CNV | ||
| • 2 eyes: | occult CNV and both VA >20/50 and large lesions (>4 disc areas) | ||
| • 3 eyes: | occult CNV but VA of less than 20/100 | ||
| • 5 eyes: | predominantly classic CNV but VA of less than 20/200 | ||
| • 2 eyes: | predominantly classic CNV occupying less than 50% of the total area of the lesion* | ||